Physician profile
Dyanesh Bapu G Ravindran
NPI 1659387132
$14,340.73
in general payments reported to CMS, 2019-2025
67 companies · $5,199 in 2025
The $5,199 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $191 · 2021: $209 · 2022: $896 · 2023: $2,701 · 2024: $4,936 · 2025: $5,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,310.95 |
| Education | $525.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,048.91 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals LP | $974.04 | 2022-2025 | Tagrisso, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $938.41 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $805.44 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $792.79 | 2019-2025 | |
| Lilly USA, LLC | $664.63 | 2019-2025 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $633.89 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $557.56 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Celgene Corporation | $526.27 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Eisai INC. | $522.10 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $429.05 | 2024-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $424.50 | 2023-2025 | Iclusig, Ninlaro, Fruzaqla |
| Incyte Corporation | $379.25 | 2022-2025 | Monjuvi, Jakafi, Zynyz |
| Genentech USA, INC. | $366.22 | 2023-2025 | Phesgo, Venclexta, Polivy |
| Pharmaessentia USA Corporation | $330.65 | 2023-2025 | Besremi |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $326.83 | 2023-2025 | Tukysa, Adcetris, Padcev |
| Glaxosmithkline, LLC. | $312.63 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $281.17 | 2021-2025 | Trodelvy |
| US Oncology Corporate, INC. | $276.11 | 2023-2024 | |
| Aveo Pharmaceuticals, INC. | $273.99 | 2023-2025 | Fotivda |
| Stemline Therapeutics INC. | $228.46 | 2023-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $217.73 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Abbvie INC. | $185.40 | 2023-2025 | |
| Array Biopharma INC | $157.17 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Alexion Pharmaceuticals, INC. | $145.61 | 2023-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $139.39 | 2021-2023 | Imbruvica |
| Adc Therapeutics America, INC. | $125.70 | 2024-2025 | |
| Genzyme Corporation | $122.71 | 2023-2025 | |
| Astellas Pharma US INC | $112.70 | 2020-2023 | Xospata |
| Novocure INC. | $107.77 | 2025 | Optune Lua (Novottf-200t) |
| Sobi, INC | $106.65 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $102.80 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $97.81 | 2023-2025 | Monoferric |
| Springworks Therapeutics, INC. | $97.67 | 2024-2025 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $96.71 | 2024-2025 | Qinlock |
| Intuitive Surgical, INC. | $92.20 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $91.61 | 2024-2025 | Onivyde |
| Beigene USA, INC. | $83.63 | 2023-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $78.36 | 2023-2025 | Libtayo |
| Exelixis INC. | $75.56 | 2023-2025 | Cabometyx |
| Taiho Oncology, INC. | $73.44 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $73.08 | 2023-2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $69.15 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $55.84 | 2025 | |
| Coherus Oncology, INC. | $54.36 | 2023-2024 | |
| Kyowa Kirin, INC. | $52.04 | 2024-2025 | Poteligeo |
| Amgen INC. | $52.01 | 2023 | Nplate, Xgeva, Vectibix |
| Tempus Ai, INC | $48.47 | 2025 | Xt Cdx |
| Kite Pharma, INC. | $45.57 | 2023 | Yescarta |
| Acrotech Biopharma INC. | $41.50 | 2022-2024 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.45 | 2025 | |
| Iovance Biotherapeutics, INC. | $34.44 | 2025 | Amtagvi |
| Mirati Therapeutics, INC. | $34.33 | 2023-2024 | Krazati |
| Invivyd INC | $34.24 | 2025 | Pemgarda |
| Fresenius Kabi USA, LLC | $33.95 | 2025 | |
| Immunocore Limited | $33.49 | 2025 | Kimmtrak |
| Shield Therapeutics INC | $29.66 | 2025 | |
| Foundation Medicine, INC. | $29.57 | 2023 | |
| Apellis Pharmaceuticals, INC. | $26.13 | 2023 | Empaveli |
| Myriad Genetic Laboratories, INC. | $23.43 | 2025 | Precisetumor |
| Biocon Biologics INC | $21.84 | 2024 | Ogivri |
| Geron Corporation | $21.69 | 2025 | Rytelo |
| Alnylam Pharmaceuticals INC. | $21.17 | 2023 | Givlaari |
| Verity Pharmaceuticals INC. | $20.75 | 2024 | Trelstar |
| Spectrum Pharmaceuticals INC. | $17.22 | 2024 | Rolvedon |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $9.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dyanesh Ravindran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.